PHARMACOVIGILANCE FLOW IN ITALY
The Italian pharmacovigilance system is based on the National Pharmacovigilance Network (RNF), which guarantees the collection, management and analysis of…
READ
VARIATIONS WITH IMPACT ON PIL/LABELLING TEXTS: SELLING OUT OF STOCKS OF MEDICINAL PRODUCTS
According to AIFA disposition n. 371 dated April 14th 2014, in the case of variations with impact on Package Information…
READNEW REGISTRATION OF MEDICINAL PRODUCTS IN COUNTRIES NOT BELONGING TO ICH REGIONS
The new registration of medicinal products in countries not belonging to ICH (International Conference on Harmonization) Regions is a challenging…
READ
THE LEGAL BASIS OF A MARKETING AUTHORIZATION APPLICATION AND THE PAEDIATRIC REGULATION
Even if for most of applications the definition of the legal basis appears to be quite obvious, the choice can…
READSPONSOR OF CONGRESSES AND MEETINGS: AIFA REQUIREMENTS
The Marketing Authorization Holder or the pharmaceutical company responsible for the commercialization of medicinal products in Italy, in order to…
READ
MEDICAL DEVICES: REGULATORY OBLIGATIONS IN ITALY
Medical devices are classified into four classes depending on their characteristics and safety profile (e.g. invasiveness , dependence on a…
READ
REGULATORY PHARMA NET MANAGING DIRECTOR, ANITA FALEZZA, INTERVIEWED @ TOPRA ANNUAL SYMPOSIUM 2015 – BERLIN
TOPRA’s Annual Symposia – covering pharmaceuticals, veterinary medicines and medical devices – are together the largest forum for European regulatory…
READ
READABILITY USER TESTING: THE DEADLINE FOR SUBMISSION FOR NATIONALLY AUTHORIZED PRODUCTS IS GETTING CLOSER
For all medicinal products registered in Italy via national procedure, the Marketing Authorization Holder is requested to submit within December…
READREGULATORY PHARMA NET EXHIBITS AT THE TOPRA ANNUAL SYMPOSIUM – BERLIN, GERMANY
From 12th till 14th of October RPN exhibits at the TOPRA Annual Symposium which will be held in Berlin at…
READ
EDUCATIONAL MATERIAL IN PILLS
Before the launch, any educational materials provided for in the Risk Management Plan of a centrally approved medicinal product shall…
READ